AstraZeneca Revenue 2006-2018 | AZN

AstraZeneca annual/quarterly revenue history and growth rate from 2006 to 2018. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
  • AstraZeneca revenue for the quarter ending June 30, 2018 was $5.155B, a 2.06% increase year-over-year.
  • AstraZeneca revenue for the twelve months ending June 30, 2018 was $22.342B, a 2.77% increase year-over-year.
  • AstraZeneca annual revenue for 2017 was $22.465B, a 2.33% decline from 2016.
  • AstraZeneca annual revenue for 2016 was $23.002B, a 6.9% decline from 2015.
  • AstraZeneca annual revenue for 2015 was $24.708B, a 6.93% decline from 2014.
AstraZeneca Annual Revenue
(Millions of US $)
2017 $22,465
2016 $23,002
2015 $24,708
2014 $26,547
2013 $25,806
2012 $27,973
2011 $33,591
2010 $33,269
2009 $32,804
2008 $31,601
2007 $29,559
2006 $26,475
2005 $23,950
AstraZeneca Quarterly Revenue
(Millions of US $)
Q2 2018 $5,155
Q1 2018 $5,178
Q4 2017 $5,777
Q3 2017 $6,232
Q2 2017 $5,051
Q1 2017 $5,405
Q4 2016 $5,585
Q3 2016 $5,699
Q2 2016 $5,603
Q1 2016 $6,115
Q4 2015 $6,399
Q3 2015 $5,945
Q2 2015 $6,307
Q1 2015 $6,057
Q4 2014 $6,716
Q3 2014 $6,609
Q2 2014 $6,762
Q1 2014 $6,460
Q4 2013 $6,939
Q3 2013 $6,250
Q2 2013 $6,232
Q1 2013 $6,385
Q4 2012 $7,282
Q3 2012 $6,682
Q2 2012 $6,660
Q1 2012 $7,349
Q4 2011 $8,656
Q3 2011 $8,213
Q2 2011 $8,430
Q1 2011 $8,292
Q4 2010 $8,617
Q3 2010 $7,898
Q2 2010 $8,178
Q1 2010 $8,576
Q4 2009 $8,945
Q3 2009 $8,200
Q2 2009 $7,958
Q1 2009 $7,701
Q4 2008 $8,193
Q3 2008 $7,775
Q2 2008 $7,956
Q1 2008 $7,677
Q4 2007 $8,170
Q3 2007 $7,150
Q2 2007 $7,300
Q1 2007 $6,966
Q4 2006 $7,154
Q3 2006 $6,516
Q2 2006 $6,625
Q1 2006 $6,180
Q4 2005 $6,286
Q3 2005 $5,789
Q2 2005 $6,130
Q1 2005 $5,743
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $99.315B $22.465B
AstraZeneca PLC is one of the top five pharmaceutical companies in the world based on sales and is a therapeutic leader in cardiovascular, gastrointestinal, oncology, anesthesia including pain management, central nervous system (CNS) and respiratory products. They are engaged in the research, development, manufacture and marketing of ethical (prescription) pharmaceuticals and agricultural products, and the supply of healthcare services.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $373.058B 17.49
Pfizer (PFE) United States $264.902B 15.51
Novartis AG (NVS) Switzerland $202.059B 17.26
Merck (MRK) United States $195.069B 17.23
AbbVie (ABBV) United States $133.211B 13.01
Eli Lilly (LLY) United States $120.201B 22.25
Sanofi (SNY) France $111.785B 14.15
Novo Nordisk (NVO) Denmark $105.487B 16.86
GlaxoSmithKline (GSK) United Kingdom $101.355B 13.53
Bristol-Myers Squibb (BMY) United States $88.755B 16.07